VALIRX PLC LS-001
Research VALIRX PLC LS-001 (EAJF) on Bullrun: market cap EUR 660.15K. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEAJF
- ExchangeF
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 660.15K
- Financial periodFY2024
- RevenueEUR 49.78K
- Revenue growth418.5%
- Net income-EUR 1.92M
- Free cash flow-EUR 1.62M
- Gross margin100.0%
Valuation Snapshot
latest market cap is EUR 660.15K.
About VALIRX PLC LS-001
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
Frequently asked questions
What is VALIRX PLC LS-001's market cap?
VALIRX PLC LS-001's market capitalization is EUR 660.15K.
What does VALIRX PLC LS-001 do?
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer;